TVB-2640 is a fatty acid synthase (FASN) inhibitor being investigated primarily for its potential in cancer therapy. It targets metabolic pathways in tumor cells that rely on de novo lipogenesis, a process often upregulated in various cancers such as non-small cell lung cancer, breast cancer, and colorectal cancer. By inhibiting FASN, TVB-2640 disrupts the production of fatty acids necessary for cancer cell membrane synthesis and signaling, leading to reduced tumor growth and increased cancer cell death. It has shown promise in preclinical and clinical studies, particularly in combination with other anticancer agents like taxanes or targeted therapies, where it enhances efficacy and may overcome resistance. Additionally, TVB-2640 is being explored for its potential in treating NASH (non-alcoholic steatohepatitis), where FASN inhibition helps reduce liver fat accumulation and inflammation. Its dual activity in oncology and metabolic disease makes it a versatile investigational compound.